Types A and B Niemann-Pick disease (NPD) result from the deficient activity of acid sphingomyelinase (ASM). Currently, no treatment is available for either form of NPD. Using the ASM knockout (ASMKO) mouse model, we evaluated the effects of ex vivo hematopoietic stem cell gene therapy on the NPD phenotype. Thirty-two newborn ASMKO mice were preconditioned with low dose radiation (200 cGy) and transplanted with ASMKO bone marrow cells which had been transduced with an ecotropic retroviral vector encoding human ASM. Engraftment of donor-derived cells ranged from 15 to 60% based on Y-chromosome in situ hybridization analysis of peripheral white blood cells, and was achieved in 92% of the transplanted animals. High levels of ASM activity (up to five-fold above normal) were found in the engrafted animals for up to 10 months after transplantation, and their life-span was extended from a mean of 5 to 9 months by the gene therapy procedure. Biochemical and histological analysis of tissues obtained 4-5 months after
Introduction
Types A and B Niemann-Pick disease (NPD) are two clinically distinct forms of a lysosomal storage disorder caused by the inherited deficiency of acid sphingomyelinase (ASM; E.C. 3.1.2.12) activity. [1] [2] [3] Type A NPD presents with failure to thrive, hepatosplenomegaly, and a rapidly progressive neurodegenerative course that generally leads to death by 3 years of age. In contrast, type B NPD is characterized by hepatosplenomegaly, pulmonary infiltrates leading to frequent respiratory infections, little or no neurological involvement, and survival into adolescence or adulthood. Sphingomyelin and cholesterol accumulate in the tissues of patients with both NPD transplantation indicated that the ASM activities were increased and the sphingomyelin storage was significantly reduced in the spleens, livers and lungs of the treated mice, major sites of pathology in type B NPD. The presence of Purkinje cell neurons was also markedly increased in the treatment group as compared with non-treated animals at 5 months after transplantation, and a reduction of storage in spinal cord neurons was observed. However, all of the transplanted mice eventually developed ataxia and died earlier than normal mice. Overall, these results indicated that hematopoietic stem cell gene therapy should be effective for the treatment of non-neurological type B NPD, but improved techniques for targeting the transplanted cells and/or expressed enzyme to specific sites of pathology in the central nervous system must be developed in order to achieve effective treatment for type A NPD. Gene Therapy (2000) 7, 1768-1776.
phenotypes, but the precise pathophysiological mechanism(s) underlying their distinct clinical course remains unknown.
In recent years the human and murine ASM cDNAs and genes have been isolated and expressed, 4-7 numerous disease-causing mutations have been identified, 8 and knockout mouse models have been produced. 9, 10 The clinical, biochemical and pathological features of the ASM-deficient (ASMKO) mice mimic human types A and B NPD, offering the opportunity to gain new insights into the pathogenesis of the disease and to develop and evaluate new therapeutic approaches.
Currently, no treatment is available for either form of NPD. Liver transplantation in an affected male with type A NPD was unsuccessful, 11, 12 and although trials of amniotic membrane transplantation and bone marrow transplantation (BMT) have been reported, [13] [14] [15] [16] only small numbers of human patients have been studied.
In contrast to these human studies, a comprehensive analysis of BMT has been carried out in the ASMKO mouse. 17, 18 BMT led to an increased life-span, histological and biochemical improvements in several clinically relevant organs, including the liver and spleen, and a delayed onset of the neurological phenotype. Thus, the use of allogeneic BMT for the treatment of type B NPD is scientifically sound, but is complicated by the lack of fully compatible sibling donors in most NPD families, the morbidity and mortality associated with the use of lethal total body irradiation and immunosuppressive reagents, as well as graft-versus-host disease (GVHD).
Autologous transplantation of genetically modified bone marrow cells (ie hematopoietic stem cell gene therapy, HSCGT) is therefore a reasonable alternative to allogeneic BMT for the treatment of this disease. 19 It eliminates the two major problems of donor availability and GVHD, theoretically resulting in decreased morbidity and mortality. Furthermore, enzymatically corrected cells obtained by gene transfer may express/secrete the enzyme at higher levels than that found in normal cells, perhaps leading to improved clinical efficacy.
The experiments described in this manuscript were undertaken to evaluate whether long-term engraftment of retrovirally transduced hematopoietic cells could be achieved using low-dose myeloablation, and if the transplantation of these cells into ASMKO newborn mice could evoke therapeutic effects. Additionally, we compared the efficacy of this therapeutic approach with the results previously obtained by the transplantation of normal bone marrow cells (ie BMT).
Results
Transplantation and engraftment Thirty-two newborn (2-day-old) ASMKO mice were each transplanted with 1 × 10 6 bone marrow cells that had been transduced with an ecotropic ASM/MFG retroviral vector (see Materials and methods for details). Sublethal (200 cGy) total body irradiation was used to facilitate engraftment along with male donor cells so that the levels of engraftment could be assessed in the female recipients by in situ hybridization using a Y chromosome-specific probe. 17 At 5 months after transplant, donor-derived WBCs were detected in 92% of the transplanted females and the percentage of these cells (ie engraftment) varied between 15 to 60%, somewhat lower engraftment percentages than those obtained previously by BMT. 17 All of the engrafted animals were determined to be positive for the presence of vector sequences in their peripheral WBCs at 3 and 8 months after transplant using a PCR screening method (not shown).
ASM activities in WBCs of transplanted ASMKO mice WBC ASM activities were measured monthly in individual animals after the transplant procedure. As shown in Figure 1 , treated ASMKO mice had significantly higher ASM activities than their normal control littermates (P Ͻ 0.002). Untreated ASMKO mice have Ͻ1% of normal WBC ASM activity. 9 Beginning at 1 month and up until the fifth month after transplant, the levels of WBC ASM activity in the treated animals progressively increased, and stabilized thereafter. However, no direct correlation between the WBC ASM activity and survival (see Figure Figure 1 2, below) was observed when individual animals were analyzed.
Serum samples from injected mice were analyzed by ELISA for the presence of anti-hASM antibodies and by immunoprecipitation to determine if such antibodies inactivated the enzyme activity. All of the successfully engrafted animals had measurable levels of anti-hASM antibodies in their plasma, but in all cases these antibodies did not inhibit the immunoprecipitated ASM activity (ie they were non-neutralizing, not shown).
Survival and growth of transplanted ASMKO mice
The effects of the gene therapy procedure on the survival of ASMKO mice are demonstrated in the Kaplan-Meier analysis shown in Figure 2 . Wild-type irradiation control animals (ie irradiated, but not transplanted) had a normal life-span (Ͼ1 year), while all of the ASMKO irradiation control mice died between between 6 and 7 months of age (average age at death 6.4 months). Increased longevity was observed in the gene therapy-treated animals. For example, at 8 months after transplant approximately 75% of the treated ASMKO animals were surviving, while by 10 months after transplant this number was reduced to 40%. Despite their increased life-span, however, ataxia became evident in the transplanted mice at about 6 months of age, and all of the treated animals (aside from those that were killed prematurely for experimental purposes), eventually died by 1 year of age. Prior to 6 months of age, the growth patterns in the treatment group were similar to that seen in the normal control group, but thereafter they underwent weight loss and followed a neurodegenerative course similar to ASMKO mice. Thus, the gene therapy procedure delayed the onset of neurological symptoms, but did not prevent them.
ASM activity and sphingomyelin content in organs Five months after treatment, a set of six transplanted animals (along with three each of the normal and affected irradiation control animals) were killed and perfused with saline solution to remove blood from the organs. Livers, spleens, lungs, kidneys, hearts and brains were then dissected and frozen. The levels of ASM activity and the sphingomyelin contents were assessed in those organs and the results are depicted in Figure 3 . Note that the levels of ASM activity in the spleens, livers and lungs of the treated ASMKO animals was approximately 90, 65 and 40% of normal, respectively, significantly above the values found in untreated ASMKO animals. 9 (P value when comparing ASM activities in these tissues between treated and untreated ASMKO mice was Ͻ0.0001.) In contrast, the levels of ASM activity found in the brains, hearts and kidneys of the treated animals were not statistically greater than those found in untreated animals (P values Ͼ0.1).
Importantly, significant correlation between the enzyme levels and the substrate clearance was observed. Indeed, in the spleens and livers, where the ASM activities were markedly elevated, the sphingomyelin accumulation was reduced to almost normal levels (P value when comparing the sphingomyelin content of these tissues between treated ASMKO and normal mice was Ͼ0.1). An intermediate situation was observed in the lungs, whereas in the brains, hearts and kidneys there was essentially no detectable ASM activity or sphingomyelin reduction. Figure 4 shows representative histological analysis of tissue sections of livers, lungs, and spleens of treated and irradiation control (ASMKO and normal) mice 5 months after transplant. Note that by 5 months of age, untreated ASMKO (panels d-f) mice exhibited massive lipid storage as compared with normal animals (panels a-c). Numerous pale foamy cells were interspersed throughout the liver and spleen sections and extensive infiltration of alveoli and septa was observed in the lungs, occluding the airways. Notably, tissues from the treated animals (panels g-i) show markedly less lipid accumulation than untreated ASMKO control animals. In Figure 5 , a reduction of storage material in the spinal cord of the treated animals is shown by azure II-methylene blue staining.
Pathological effects
In order to investigate the effects of HSCGT on the Pukinje cell (PC) loss which occurs in ASMKO mice, we compared control and treated cerebella sections (5 months transplantation) immunoreacted with calbindin antiserum, a calcium binding protein expressed exclusively in PC ( Figure 6 ). Note the marked PC loss in an untreated ASMKO control (panel a) as compared with a representative section from a treated mouse (panel b). Indeed, just one lobe of the cerebellum shows PC staining in the untreated ASMKO animal, while PCs are present 
Figure 4 Non-CNS histology. Hematoxylin-eosin staining of liver, lung, and spleen sections from representative normal control (a-c), ASMKO control (d-f), and treated ASMKO (g-i) mice 5 months after transplantion (original magnification ×200).

Discussion
The aim of the present study was to determine whether HSCGT could be an effective therapeutic approach for types A and/or B NPD. The NPD (ASMKO) mouse model exhibits both CNS and visceral pathology very similar to human NPD patients, and is an excellent system in which to evaluate this and other therapeutic strategies. We previously reported the results of BMT in the ASMKO mouse, 17, 18 and found that a sublethal preconditioning regimen in newborn animals could lead to high-level engraftment without causing increased mortality or pathological artifacts. In addition, we demonstrated significant, but incomplete, alteration of the phenotype in the treated mice. In particular, the histological phenotype was markedly improved in the reticuloendothelial organs and the onset of ataxia was delayed (concurrent with an enhanced retention of PC neurons), but all of the treated animals eventually developed neurological symptoms and died prematurely.
HSCGT has several potential advantages over BMT for human NPD patients, including the fact that the transplanted cells do not need to be derived from HLA-compatible normal or heterozygous donors. In addition, transduced, autologous cells can potentially overexpress the transgene, perhaps leading to an enhanced therapeutic response. In the present study greater than normal levels of WBC ASM activities were obtained in several treated animals over the 10 month evaluation period, however the effects of HSCGT were essentially the same as those for BMT: ie despite the increased life-span, markedly improved histological and biochemical findings in the visceral organs and delayed onset of neurodegeneration, all of the transplanted mice eventually developed ataxia and died prematurely.
Of note, the levels of engraftment achieved by the gene therapy protocol, as determined by in situ hybridization with a Y chromosome-specific probe, were lower than those obtained by BMT, 17 despite the fact that the transplantation procedure (eg cell number, irradiation dose) was the same. These results highlight several important differences between the two therapeutic approaches. For example, when transplanting normal bone marrow no cell manipulations were performed, ie the total content of marrow cells harvested from the bones of normal donors was transplanted without cell culture or fractionation. In the gene therapy protocol, a population of mononuclear cells, isolated by discontinuous density gradient centrifugation, was kept in culture for 2 days in the presence of growth factors and transduced with the retroviral vector. This may account for the lower levels of engraftment observed. 20, 21 However, despite lower engraftment, higher levels of enzymatic activity were generally detected in the WBCs and organs of the gene therapy-treated animals when compared with those receiving BMT. These data are consistent with those of other investigators who have shown long-term and high-level expression of transgenes in mice or rats transplanted with MFG-transduced hematopoietic cells. [22] [23] [24] Concordant with the high level enzymatic expression, an almost complete correction of the reticuloendothelial system pathology, which was observed only when high-level engraftment (ie Ͼ90%) was achieved by BMT, 18 was seen in gene therapy-treated animals engrafted 30% or less.
The loss of PC neurons in the cerebella of NPD mice is one of the major features of their CNS pathology. 9, 18, 25 It is also the likely cause of the progressive ataxia, which eventually leads to death. It has been reported that ceramide is an essential factor required for survival of cerebella PC neurons. 26 Inhibition of ceramide synthesis resulted in decreased cell survival, accompanied by induction of apoptotic cell death and aberrant dendritic differentiation of PC, with no detectable changes in other cerebellar neurons. 26 In contrast, upon exposure to bacterial sphingomyelinase PC survival and dendritic branching increased, presumably due to increased ceramide production. In order to monitor the loss of PC neurons in the cerebella of treated ASMKO animals, we performed immunohistochemistry using a calbindin antiserum. Calbindin D28k is a member of the large EF-hand family that is believed to function, in part, as a cytosolic calcium buffer, and encodes a calcium binding protein that is expressed in the cerebellum exclusively in PC. [27] [28] [29] Our results demonstrated that at 5 months after transplantation, there was an increased number of PC in treated mice as compared with affected, irradiation control mice. These findings were most likely due to the presence of retrovirally transduced, bone marrow-derived microglial cells in the CNS that were capable of secreting ASM in sufficient amounts to delay the disease-specific cell death in PC neurons. Similar findings were observed in our BMT studies. 18 It is also notable that these results were obtained despite the fact that no detectable increases in ASM activity could be found in the brain homogenates of the treated animals. This result is consistent with the fact that very few donor-derived cells were able to cross the blood-brain barrier following sublethal irradiation and transplantation, 17 and indicated that very low levels of ASM are sufficient to delay PC death, but not prevent it.
Thus, like allogeneic BMT, HSCGT appears to be a viable therapeutic option for type B NPD. It is particularly notable that equivalent histological/clinical effects were achieved by both the BMT and HSCGT procedures, despite the fact that lower levels of engraftment were obtained by the latter. This result, coupled with the fact that the need for immunosuppressive conditioning is significantly reduced when transplanting autologous versus allogeneic cells, supports the notion that HSCGT may be a suitable treatment for human type B NPD patients. However, it must be cautioned that despite these encouraging results in the mouse model, achieving the same results in human patients remains problematic at the present time because currently available gene transfer vectors are not capable of efficiently transducing human hematopoietic stem cells. Thus, allogeneic BMT remains the only therapeutic option available to type B NPD individuals. With regards to type A NPD, the data indicate that low levels of ASM expression in the CNS can lead to partial neurological improvements, but that like BMT, is unlikely to prevent the rapid, neurodegenerative course of this disease. Thus, new approaches must be developed to improve delivery of the transplanted cells to the CNS and/or increase vector-derived ASM expression in the brain of type A NPD children for effective treatment.
Materials and methods
Retroviral vector construction and amphotropic producer cell preparation
The ASM/MFG retroviral vector was constructed by inserting the full-length human ASM cDNA (hASM) into the MFG vector as previously described. 30 Briefly, PCR mutagenesis was used to introduce a NcoI restriction site into the translation initiation codon of the wild-type hASM sequence in order to optimize translation and to facilitate cloning. To generate amphotropic retroviral packaging cell lines, the ASM/MFG vector was co-electroporated with the pSV2neo plasmid into envAM12 amphotropic packaging cells 31 and subjected to G418 selection. Media was collected from individual viral producer cell clones, and the producer clone that led to the highest ASM activity after transduction of NIH-3T3 cells was used for subsequent experiments. The titer of the producer clone was estimated by measuring the increase in ASM activity obtained after transduction of NIH-3T3 cells with serial dilutions of the producer cell media, as well as by Southern blotting. Similar methods of estimating titers based on enzymatic activity have been published for several other MFG vectors in the absence of a selectable marker system. 32, 33 Ecotropic producer cell preparation To prepare ecotropic producer cells, the amphotropic producer cell line with the highest titer was grown to approximately 80% confluency in Dulbecco's modified Eagle's media (DMEM, GibcoBRL, Gaithersburg, MD, USA) containing 20% fetal calf serum and antibiotics. After 24 h, the media was harvested, concentrated using 300K Macrospec filter tubes (Pall Filtron Corporation, East Hills, NY, USA), combined with fresh media containing antibiotics and 8 g/ml polybrene (Sigma, St Louis, MO, USA), and transferred to a 10-cm dish containing the gp86 ecotropic packaging cell line. 34 The process was repeated three times over a 3-day period, and the transduced ecotropic producer cells were then harvested and diluted to a final concentration of 100 cells per 10 ml for replating and subsequent ring cloning. DNA was prepared from individual ecotropic cell clones and subjected to quantitative PCR (see below), and the clone exhibiting the highest copy number of the provirus was retained and used to transduce ASMKO mouse bone marrow cells.
Gene Therapy
Donor cell preparation
The ASMKO mouse colony was established from heterozygous breeding pairs obtained by gene targeting of 129/Sv embryonic stem cells followed by microinjection into C57BL/6 blastocysts. 9 ASMKO male mice (8-12 weeks old) were used as the source of donor cells. To obtain nucleated bone marrow cells, donor animals were pretreated with 5FU (150 mg/kg) 48 h before death by cervical dislocation. The bone marrow cells were harvested from the tibias and femurs by flushing the medullary cavities with buffered Hanks solution (10 mol/ml Hepes, pH 7.5) and a 27-gauge needle. Singlecell suspensions were obtained by passing cells through a 40 m nylon cell strainer (Becton Dickinson Labware, Franklin Lakes, NJ, USA). Low-density bone marrow cells (Ͻ1.085 g/cm 3 ) were isolated by discontinuous density gradient centrifugation using Nycoprep (Nycomed Pharma AS, Oslo, Norway), 35 and washed with buffered Hanks solution containing 5% heat-inactivated fetal calf serum. The cells were then counted, diluted to the desired concentration, and retrovirally transduced as described below.
Retroviral transduction of bone marrow cells
The ecotropic viral supernatants were concentrated using 300K macrosep filter tubes according to the manufacturer's instructions. To achieve retroviral transduction, approximately 1 × 10 9 bone marrow cells from male ASMKO donors were cultured for 48 h in 10 ml of DMEM containing concentrated ecotropic ASM/MFG retroviral vector, 20% heat-inactivated fetal calf serum and antibiotics. The cultures also contained SCF (50 ng/ml), IL-3 (20 ng/ml), IL-6 (10 ng/ml) (Genzyme, Cambridge, MA, USA) and 8 g/ml polybrene. [36] [37] [38] [39] After the first 24 h, the medium was changed to fresh medium containing newly harvested and concentrated virus, fresh growth factors, and polybrene.
PCR analysis to detect the ASM/MFG vector A modification of our previously described procedure was used. 30 The endogenous murine and MFG-encoded human ASM sequences were amplified using one common sense primer, 5Ј-TGCTGAGGATCGAGGAGA CAA-3Ј (P1) constructed from human and murine ASM exon 3, and two species-specific antisense primers, 5Ј-GGGTAGAGTGACAGAAGATTGA-3Ј (P2) and 5Ј-GGCACAAGAGTAGCCAGACG-3Ј (P3), constructed from murine ASM intron 3 and human ASM exon 6, respectively. Primer pair P1 and P2 amplified a 211-bp genomic murine-specific ASM product, while primer pair P1 and P3 amplified a 554-bp product from the humanspecific MFG vector. Each amplification reaction (approximately 100 l final volume) contained 200 pmol of primer P1, 100 pmol each of primers P2 and P3, 300 ng of genomic DNA, 1x PCR buffer, 1.5 mm MgCl 2 , 5U of Taq polymerase (Promega, Madison, WI, USA) and 200 mm each of dNTPs. A standard curve was generated using DNA mixtures as previously described. 20 Following amplification (30 cycles, each consisting of 1 min at 93°C, 61°C, and 72°C), the PCR products were separated by electrophoresis on 1.5% agarose gels and stained with ethidium bromide. The intensity of the bands was determined using the NIH Imager software package.
Transplantation of transduced cells
Thirty-two 2-day-old newborn ASMKO mice were used as recipients. Before receiving the transplant, the recipients were subjected to a single total body irradiation dose of 200 cGy from a dual 137 Cs source (dose rate, 80 cGy/min). Each animal received a total of 1 × 10 6 cells/g of body weight injected intravenously. Age-matched littermates (normal and ASMKO, n = 5 for each) were used as irradiation controls (ie irradiated, but not transplanted). The animals were maintained on a 12-h light/dark cycle, water ad libitum, and Purina rodent chow 5001. No antibiotics or other supportive care were given to any of the animals before or after transplantation.
Post-transplant evaluation
The weights of the transplanted and control animals were registered monthly. Peripheral blood was also obtained by retinal orbit bleeding for monthly enzyme analysis in white blood cells (WBCs) (see below).
Y chromosome in situ hybridization
Blood samples were collected 5 months after transplantion to estimate engraftment in female recipients. WBCs were isolated using hemolytic buffer (0.1 m NH 4 Cl, 12 mm NaHCO 3 , 10 mm EDTA, pH 8.0), fixed in Carnoy's solution (methanol-acetic acid 3:1), and spotted on microscope slides. The cells were treated with 0.1 m HCl containing 0.05% Triton X-100 for 7.5 min at 37°C, fixed in 1% buffered paraformaldehyde (pH 7.4) for 15 min at 24°C, and then dehydrated in ethanol. Hybridizations were performed by incubating the slides overnight in a humidified chamber at 37°C with a solution (2× SSC, 50% formamide, 10% dextran sulfate, 0.1% Tween 20, 0.5 mg/ml salmon sperm DNA) containing 4 ng/l of the biotinylated mouse Y chromosome-specific probe (M34). 40 After hybridization, the slides were washed and developed using a fluorescein avidin conjugate (5 g/ml) (Sigma, St Louis, MO, USA), followed by amplification with biotinylated anti-avidin (2 g/ml) (Vector Laboratories, Burlingame, CA, USA). Subsequently, a second incubation/amplification with the fluorescein avidin conjugate was carried out to maximize the detection sensitivity. The cells were then counter-stained with propidium iodide (100 g/ml) (Sigma) and mounted in antifade medium (10 mm Tris-HCl pH 7.5 containing 20 mg/ml of DABCO (triethylenediamine-1,4-diazabicyclo[2.2.2]octane; Sigma) in glycerol). 300 nuclei were scored to determine the percentage of donor-derived cells in the blood of the transplant recipients.
Enzyme-linked immunoabsorbent assay (ELISA) and immunoprecipitation In order to detect the presence of antibodies against the expressed recombinant hASM, ELISA assays were performed on plasma from treated and untreated mice. Purified hASM was incubated 18 h in 96-well microtiter plates. The wells were washed 3× with washing buffer 1 (WB1, 10 mm Tris pH 7.5, 150 mm NaCl, 0.05% Tween 20), then blocked for 1 h with 3% BSA in PBS at room temperature. Dilutions of treated and untreated mouse plasma in WB1 (100 l at 10 −2 , 10
, 10 −4 dilution) were added to the wells and incubated at 37°C for 3 h. The wells were washed 3× with WB1 followed by the addition of 100 l of peroxidase-conjugated goat anti-mouse IgG (Sigma) (1:500 dilution in WB1) and a 2 h incubation at room temperature. The wells were washed again 3× with WB1 and 2× with washing buffer 2 (10 mm Tris pH 7.5, 150 mm NaCl). Peroxidase substrate was then added to the wells (100 l) and incubated at room temperature for 30 min. An automated ELISA plate reader was used to determine the absorbance at 405 nm.
Immunoprecipitation assays were used to determine if the antibodies present in the treated mice were inactivating the expressed enzyme. A solution of 500 U of hASM, 1 ml of PBS, 10 l of mouse plasma (treated or control) and 1 mg/ml BSA was incubated for 18 h at 4°C on a rotating wheel. Subsequently, 100 l of protein Gsepharose diluted 1:1 in PBS was added to the solution and incubated for 4 h at 4°C. After centrifugation at 14 000 r.p.m. for 2 min, supernatants and pellets were assayed for ASM activity.
ASM activity assay
Sphingomyelin covalently linked to the fluorescent probe BODIPY (BODIPY dodecanoyl sphingosyl phosphocholine; BOD12-SPM) was synthesized as previously described for lissamine rhodamine sphingomyelin (LR12-SPM), 41 except that BODIPY dodecanoic acid (Molecular Probes, Eugene, OR, USA) was condensed with sphingosyl phosphocholine. Cleavage of BOD12-SPM by ASM releases fluorescent ceramide, which can be quantified after separation by TLC or organic extraction. WBCs or tissues were obtained as previously described 18 and homogenized in 0.2% Triton X-100 on ice using three 10 s bursts of a Potter-Elvehjem tissue homogenizer (Thomas Scientific, Sweedesboro, NJ, USA). Total protein was determined by the method of Stein et al. 42 The standard 15 l ASM assay mixture consisted of 10 l of sample (homogenized cells or tissues), and 2 nmol of BOD12-SPM suspended in 0.1 m sodium acetate buffer, pH 5.2, containing 0.6% Triton X-100 and either 5 mm EDTA (for detection of the non-zinc-dependent ASM activity) or 0.1 mM ZnCl 2 (for detection of the zinc stimulated ASM activity). 43 After incubating the assay mixture at 37°C (up to 3 h), the samples were loaded on thin layer chromatography plates (TLC LK6 D Silica gel 60, Whatman, Clifton, NJ, USA) and resolved using chloroform/methanol (95:5 v/v). After resolution, the band containing the fluorescently labeled ceramide was scraped from the TLC plates, extracted in chloroform/methanol/water (1:2:1 v/v) for 15 min at 55°C, and quantified in a spectrofluorometer (fluorescence spectrophotometer 204-A, Perkin Elmer). The instrument was set at excitation and emission wavelengths of 505 and 530 nm, respectively.
Sphingomyelin analysis
Sphingomyelin (SPM) levels were determined from the phosphate content in each sample. 44 Tissues (brain, liver, lung, and spleen) were homogenized in chloroform/ methanol (1:2 v/v) for lipid extraction. Alkaline phospholipid hydrolysis was performed on the liver, lung, and spleen samples in 0.4 N KOH/90% methanol for 2 h at 55°C. To avoid interference from plasmologen and other phospholipids in the brain extracts, acidic hydrolysis was carried out on these samples using 0.6 m HCl in ethanol for 30 min at 37°C before the alkaline hydrolysis. After hydrolysis, the samples were incubated with perchloric acid (70%) for 40 min at 180°C followed by treatment with 0.5% ammonium molybdate and Fiske and Subbarow reducer (4 mg/ml; Sigma) for 10 min at 100°C. Absorbance at 830 nm was measured in a spectrophotometer (Model 1201, Milton Roy Spectronic, Rochester, NY, USA).
Tissue preparation for histology Mice were anesthetized with ketamine (Sigma; 0.5 g/kg of body weight) and subjected to cardiac perfusion. An incision was made in the right atrium to allow blood to flow out, and a cannula was introduced through the left ventricle into the aorta, delivering 50 ml of warm 0.9% NaCl solution. Tissue samples for light microscopy were fixed in buffered 10% formalin, paraffin-embedded, sectioned, and stained with hematoxylin and eosin. CNS samples were collected after glutaraldehyde perfusion, postfixed in osmiun tetroxide, Epon-embedded, sectioned, and stained with azure II-methylene-blue.
Purkinje cell immunodetection
Tissues were fixed by vascular perfusion with 4% buffered formaldehyde (from paraformaldehyde) and 50 m sections were obtained from the cerebella by Vibratome. Sections were treated with methanol/hydrogen peroxide to eliminate endogenous peroxidase activity, blocked with a solution of 10% normal goat and 10% normal donkey serum, 1% bovine serum albumin, 0.1% gelatin and 0.01% sodium azide in PBS, followed by an 18 h incubation with rabbit anti-calbindin (Sigma) antiserum (1:5000 dilution prepared in the same buffer). Sections were then washed for 4-8 h in PBS and incubated 18 h in a diluted anti-rabbit immunoreagent which consists of a peroxidase-conjugated Fab2 fragment (raised in donkey), cross-absorbed to be nonreactive to mouse immunoglobins (Amersham). Following 4-8 h of wash, sections were developed in a standard DAB-hydrogen peroxide mixture, dried, and mounted under coverslips.
Statistical analysis
Kaplan-Meier actuarial analysis (Figure 2 ) was performed using the computer-assisted system for patient data entry and retrieval (CASPER) statistical package. For the data depicted in Figures 1 and 3 , the mean values are plotted along with the standard errors of the mean. P values were calculated using a paired t test.
